Building systems that work for real-world evidence development and use

November 28, 2024




Rebeccah Marsh PhD, CE rmarsh@ihe.ca


The aim

TIMELY, APPROPRIATE, AND EQUITABLE ACCESS TO NOVEL THERAPIES


Real-world data and evidence is key for access to innovative therapies




Encouraging a broader view



RWD also key for sustainability and innovation



Fueling a system of interconnected outcomes




Real-world example

Using RWE to improve access to children's mental health care



Enablers and incentives for RWE use in decision making



We need a systems approach to RWE policy & practice

Government Gouvernement of Canada du Canada	Search Canada.ca	
MENU 🗸		
Canada.ca > Health > Health system and services > Health care s	system > National Pharmacare	
The National Strategy for Dru	gs for Rare Diseases	
On this page	Pan-Canadian Artificial Intelligence Strate	gv
<u>Overview</u>		-87
Working with provinces and territories		
• <u>Research partners and initiatives</u>		
• <u>Resources for patients and practitioners</u>		
Overview		
	Through the Pan-Canadian Artificial Intelligence Strategy, the Government of	of Canada is ir
On March 22, 2023, the Government of Canada anno	adoption of artificial intelligence across Canada's economy and society. The	second phase
Drugs for Rare Diseases. This will help increase acce	Canada's world-class talent and research capacity with programs to enable commercializa	
affordable for patients across Canada. The strategy	ensure that Canadian ideas and knowledge are mobilized and commercializ	ed here at ho
1. Support patient outcomes and sustainability	The Pan-Canadian Artificial Intelligence Strategy has three pillars, which bri	ng together pa
2. Invest in innovation		
3. Seek national consistency		
4. Collect and use evidence		



Pan-Canadian Health Data Strategy: Toward a world-class health data system

Expert Advisory Group - Final Report May 2022